Delivery Order SPE2DB20D3101-SPE2DB23FRDW6
- Not listed
- This federal contract award is for the delivery of OFEV 100 MG CAPSULE 60S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $16,378.86 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 19, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Delivery Order valued at $7,915.84 for the supply of OFEV 100 MG CAPSULE 60S, a pharmaceutical product. The award has an ultimate completion date of May 1, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award is a delivery order valued at $8,590.58 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award was made by the Defense Logistics Agency (DLA), a defense agency, to provide 150 mg OFEV capsules. The contract is for a firm fixed price and has an ultimate completion date of July 14, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite...
- This federal contract award, valued at $7,905.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OFEV 150 MG CAPSULE 60S, a medical product, with a completion date of November 15, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999, which AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary...
- This federal contract award is for the delivery of Ofev 100 mg capsules to support the Defense Logistics Agency (DLA). The $7,915.84 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. The contract has an ultimate completion date of May 23, 2024 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of OFEV 150 MG capsules. The $15,811.12 firm-fixed-price contract has an ultimate completion date of April 23, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. The IDC serves as the primary vehicle for the company to...
- This federal contract award is for the delivery of Ofev 150 mg capsules to the Defense Logistics Agency (DLA). The contract, valued at $5,813.46, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on December 15, 2022. The contract is a delivery order with a firm fixed price and has a period of performance through January 9, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $7,905.56 contract is for the delivery of OFEV 150 MG CAPSULE 60S, a specialty pharmaceutical product, with a performance period through April 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $7,905.56 to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Cencora, Inc. The contract is for the supply of the prescription drug OFEV 150 MG CAPSULE 60S and has a period of performance through May 24, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued up to $999,999,999.00 through...
- This federal contract award is for the delivery of OFEV 150 MG CAPSULE 60S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $7,905.56 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical and medical products to the U.S. government. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB23FRDW6Delivery Order
This federal contract award is for the delivery of OFEV 150 MG capsules to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $15,242.06, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a delivery order with a firm fixed price and an ultimate completion date of March 22, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This contract award is likely a specific delivery order under that larger IDC. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.2k | 3/1/23 |